Adrien Joseph, Stéphanie Harel, Laurent Mesnard, Cédric Rafat, Silène Knapp, Anne Rumpler, Carole Philipponnet, Christophe Barba, Jean-Michel Rebibou, David Buob, Alexandre Hertig, Jacques Vargaftig, Jean-Michel Halimi, Bertrand Arnulf, Anne-Sophie Bretaud, Bérangère Joly, Steven Grangé, Paul Coppo
BACKGROUND AND HYPOTHESIS: Carfilzomib, a new proteasome inhibitor indicated for patients with relapsed/refractory myeloma, has been associated with cases of thrombotic microangiopathy (CFZ-TMA). The role of variants in the complement alternative pathway and therapeutic potential of complement blockade with eculizumab remain to be determined. METHODS: We report 37 cases of CFZ-TMA recorded in the French reference center for TMA with their clinical characteristics, genetic analysis and outcome according to treatments...
April 24, 2024: Nephrology, Dialysis, Transplantation